BioNTech SE [●] ORDINARY REGISTERED SHARES, NO PAR VALUE, IN THE FORM OF [●] AMERICAN DEPOSITARY SHARES Underwriting AgreementBioNTech SE • July 21st, 2020 • Biological products, (no disgnostic substances) • New York
FIRST AMENDMENT TO THE LICENSE AGREEMENT (BROAD REFERENCE NO. OLC2015079)License Agreement • July 21st, 2020 • BioNTech SE • Biological products, (no disgnostic substances)
This First Amendment to the License Agreement (the “Amendment”), effective as of January 16, 2018 (the “Amendment Effective Date”), is between The Broad Institute, Inc. (“Broad”) and Neon Therapeutics, Inc. (“Company”).
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, ANDBioNTech SE • July 21st, 2020 • Biological products, (no disgnostic substances)
This Amendment No 5 is made and entered into as of May 08th, 2020 (Amendment No 5 Effective Date) by and between BioNTech SE, a German corporation having its principal office at An der Goldgrube 12, 55131 Mainz, Germany (Biontech) and Genmab A/S, CVR no. 21023884, a Danish corporation having its principal office at Kalvebod Brygge 43, DK-1560 Copenhagen V, Denmark, (Genmab).
License Agreement by and between The Broad Institute, Inc. and Neon Therapeutics, Inc. November 13, 2015License Agreement • July 21st, 2020 • BioNTech SE • Biological products, (no disgnostic substances) • Massachusetts
This License Agreement (this “Agreement”) is entered into as of this 13th day of November, 2015 (the “Effective Date”), by and between the Broad Institute, Inc., a non-profit Massachusetts corporation, with a principal office at 415 Main Street, Cambridge, MA 02142 (“Broad”), and Neon Therapeutics, Inc., a Delaware corporation with a principal office at 215 First Street, Cambridge, MA 02142 (“Company”). Company and Broad are each referred to herein as a “Party” and collectively as the “Parties”.
